Meditation and Cancer, Pilot Feasibility Study (MAEva Pilot Study)
Meditation and Cancer: Effectiveness of the MAEva Program on Symptoms and Quality of Life. Pilot Feasibility Study. (MAEva Pilot Study)
MAEVA, which stands for Meditation, Acceptance and Commitment towards Values, is an open and circular program, made up of 3 themed sessions, following a weekly rhythm. It is proposed here to study this program over a period of 3 months, which will give participants the opportunity to complete up to three complete cycles.
This program is based on the practice of and the processes of acceptance and commitment therapy. These approaches, used for several years, have proven their effectiveness in the management of stress, chronic anxiety, insomnia, chronic pain, distress in the face of chronic disease, as well as in the prevention of depressive relapses and management of impulsivity.
Unlike conventional 8-week meditation programs, the MAEva program allows patients to enter the study at any stage of the disease (within, outside the exclusion criteria) and from any session and to participate according to their possibilities.
The patient can participate in a weekly session of the program for 3 cycles. During the sessions, it will be proposed to train meditative practices and 3 different themes will be addressed (one theme per session): Meditation, Acceptance and Commitment to values.
.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vandœuvre-lès-Nancy, France, 54519
- Institut de cancerologie de Lorraine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Major patient
- Patient with non-metastatic prostate or breast cancer
- Newly diagnosed patients or those undergoing treatment
- Patient able and willing to follow all study procedures in accordance with the protocol.
- Patient having understood, signed and dated the consent form.
- Patient affiliated to the social security system
- Patient able to remain in a sitting position during the 2-hour session
Exclusion Criteria:
- Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons.
- Presence of an acute psychiatric disorder: depression in acute phase, unstabilised bipolar disorder, psychotic disorders (delusions, hallucinations), etc.
- Presence of recurrent uncontrolled panic attacks (notably linked to hypochondriac concerns)
- Presence of latent or patent post-traumatic stress disorder
- Lack of motivation to meditate
- Insufficient attentional resources to meditate: major problems with attention, memory or reasoning
- Patient with metastatic cancer.
- Presence of cognitive and neurocognitive disorders and deficits
- Presence of deafness
- Membership in a meditation programme prior to inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Receiving mindfulness open and circular program
|
At the end of the first and the last cycle, as well as 3 weeks after the last cycle, the patient will be invited to answer different questionnaires evaluating his or her quality of life (HADS, QLQC30, FA12). This is why the observation period is 3 months (3 cycles of 3 weeks + 3 weeks). Similarly, some of the patients included in the study will be asked to complete a semi-structured interview at the end of the MAEva programme. Patients and nursing staff participating in the study will be asked to complete a satisfaction questionnaire |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the feasibility and acceptability of the MAEva programme to patients in a specialised care facility
Time Frame: 3 months
|
Patient participation rate and number of sessions performed per patient
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved patient well-being
Time Frame: 3 months
|
Hospital Anxiety et Depression Scale (HADS) and Quality of Life Questionnaire C30 (QLQC30) and QLQ -FA12 (EORTC Cancer Related Fatigue)
|
3 months
|
|
Measure patient satisfaction
Time Frame: 3 months
|
Satisfaction questionnaire [1: unsatisfied - 10 very satisfied]
|
3 months
|
|
Measure care staff satisfaction
Time Frame: 3 months
|
Satisfaction questionnaire [1: unsatisfied - 10 very satisfied]
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: François Bourgognon, PhD, Institut de cancerologie de Lorraine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-A03205-34
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.